Matrix Metalloproteinases and Minocycline: Therapeutic Avenues for Fragile X Syndrome
Joint Authors
Siller, Saul S.
Broadie, Kendal
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-05-20
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Fragile X syndrome (FXS) is the most common known genetic form of intellectual disability and autism spectrum disorders.
FXS patients suffer a broad range of other neurological symptoms, including hyperactivity, disrupted circadian activity cycles, obsessive-compulsive behavior, and childhood seizures.
The high incidence and devastating effects of this disease state make finding effective pharmacological treatments imperative.
Recently, reports in both mouse and Drosophila FXS disease models have indicated that the tetracycline derivative minocycline may hold great therapeutic promise for FXS patients.
Both models strongly suggest that minocycline acts on the FXS disease state via inhibition of matrix metalloproteinases (MMPs), a class of zinc-dependent extracellular proteases important in tissue remodeling and cell-cell signaling.
Recent FXS clinical trials indicate that minocycline may be effective in treating human patients.
In this paper, we summarize the recent studies in Drosophila and mouse FXS disease models and human FXS patients, which indicate that minocycline may be an effective FXS therapeutic treatment, and discuss the data forming the basis for the proposed minocycline mechanism of action as an MMP inhibitor.
American Psychological Association (APA)
Siller, Saul S.& Broadie, Kendal. 2012. Matrix Metalloproteinases and Minocycline: Therapeutic Avenues for Fragile X Syndrome. Neural Plasticity،Vol. 2012, no. 2012, pp.1-9.
https://search.emarefa.net/detail/BIM-1002332
Modern Language Association (MLA)
Siller, Saul S.& Broadie, Kendal. Matrix Metalloproteinases and Minocycline: Therapeutic Avenues for Fragile X Syndrome. Neural Plasticity No. 2012 (2012), pp.1-9.
https://search.emarefa.net/detail/BIM-1002332
American Medical Association (AMA)
Siller, Saul S.& Broadie, Kendal. Matrix Metalloproteinases and Minocycline: Therapeutic Avenues for Fragile X Syndrome. Neural Plasticity. 2012. Vol. 2012, no. 2012, pp.1-9.
https://search.emarefa.net/detail/BIM-1002332
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1002332